Synovio Therapeutics
Drug Candidate for Osteoarthritis Therapy
Health Tech & Life Sciences
Non Active, Aug 2026 ceased to operate
Company Overview
Snapshot
Founded in January 2025 by Adi Sagiv Meister, Synovio Therapeutics operates with 1–10 employees. The company secured a grant from the Israel Innovation Authority in September 2025, marking its first disclosed funding round.
Business overview
Synovio Therapeutics is a Health Tech & Life Sciences company focused on developing a novel small molecule, Fenchone 1D, as a drug candidate for Osteoarthritis therapy. This molecule acts as a specific agonist to the CB2 receptor. The company operates within the Pharma & Medical Biotechnology sector, specifically in Drugs Discovery & Development, targeting the Life Sciences and Pharmaceuticals markets with a B2C business model.
Log in to access full profile ›Company Intelligence Q&A
- What is the primary focus of Synovio Therapeutics?
- Synovio Therapeutics is developing a novel small molecule, Fenchone 1D, intended as a drug candidate for Osteoarthritis therapy, specifically targeting the CB2 receptor.
- When was Synovio Therapeutics founded?
- Synovio Therapeutics was founded in January 2025.
- Who is the founder of Synovio Therapeutics?
- Adi Sagiv Meister is the founder of Synovio Therapeutics.
- What is the current operational status of Synovio Therapeutics?
- Synovio Therapeutics ceased to operate in August 2026.
- Which organization provided funding to Synovio Therapeutics?
- In September 2025, Synovio Therapeutics received a grant from the Israel Innovation Authority.